Search
Tecovirimat
go.drugbank.com/drugs/DB12020ApprovedInvestigational[A35131,A35143] Tecovirimat was approved by the FDA in July 2018 as the first drug ever approved to treat smallpox. … [A35133,L3614] Tecovirimat is an antiviral drug that was identified via a high-throughput screen in 2002.
Lenacapavir
go.drugbank.com/drugs/DB15673ApprovedInvestigationalHIV/AIDS remains an area of concern despite the introduction of numerous successful therapies, mainly due to the emergence of multidrug resistance and patient difficulty in adhering to treatment regimens … [L42995] On December 22, 2022, it was also approved by the FDA.[L44473]
Hydroxycitronellal
go.drugbank.com/drugs/DB14187ApprovedHydroxycitronellal has also been shown to be a dermatologic irritant and allergen, and as a result commercially available products are restricted by the International Fragrance Association (IFRA) to contain
Alprazolam
go.drugbank.com/drugs/DB00404ApprovedIllicitInvestigational[A18125] Alprazolam was given FDA approval on October 16, 1981.[L6148] … [A18125] Alprazolam's adverse effects are generally related to the sedation it can cause.
Mixtures: NEUPAX DUO-SProducts: Nu-alpraz Tab 0.5mg, Nu-alpraz Tab 0.25mgInfigratinib
go.drugbank.com/drugs/DB11886ApprovedInvestigationalWithdrawn[L34304] The FDA later announced the final withdrawal of the approval of infigratinib for this indication on May 16, 2024: This decision was based on the sponsor's request due to clinical trial recruitment … cholangiocarcinoma in adults with a fibroblast growth factor receptor 2 (FGFR2) fusion or another rearrangement as detected by an FDA-approved test.
Cupric sulfate
go.drugbank.com/drugs/DB06778ApprovedThe average daily intake of copper in the USA is approximately 1 mg Cu with the diet being a primary source [A32221]. … Copper is an essential trace element and an important catalyst for heme synthesis and iron absorption. After zinc and iron, copper is the third most abundant trace element found in the human body.
Mixtures: Se-Tan PLUS, Pnv-VP-UProducts: Micro CuPalbociclib
go.drugbank.com/drugs/DB09073ApprovedInvestigationalIt is a second generation cyclin-dependent kinase inhibitor[A176798] selected from a group of pyridopyrimidine compounds due to its favorable physical and pharmaceutical properties. … [L5867] It was originally FDA approved on March 2015 for the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer and its indications were updated in April 2019 to include male
Synonyms: 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-8h-pyrido(2,3-d)pyrimidin-7-one, 6-acetyl-8-cyclopentyl-5-methyl-2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}pyrido[2,3-d]pyrimidin-7(8H)-oneSomatrogon
go.drugbank.com/drugs/DB14960ApprovedInvestigational[L39362] In October 2021, Health Canada approved somatrogon under the market name NGENLA as the long-term treatment of pediatric patients who have growth failure due to an inadequate secretion of endogenous … [L39060] In June 2023, the FDA approved the use of somatrogon also for the treatment of pediatric growth hormone deficiency.
Upadacitinib
go.drugbank.com/drugs/DB15091ApprovedInvestigational[A189165] Despite a variety of therapeutic agents available for treatment, up to 40% of the patients do not respond to current therapies, including biological therapies. … [A189165] The FDA approved upadacitinib in August 2019 and it is used for the treatment of active rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, ulcerative colitis, and ankylosing spondylitis
Retapamulin
go.drugbank.com/drugs/DB01256ApprovedRetapamulin, marketed by GlaxoSmithKline as the ointment Altabax, is an antibiotic for skin infections like impetigo. It was approved by the FDA in April 2007.